Immupharma pleased with Lupuzor trial progress

Specialist drug discovery and development company ImmuPharma updated the market on Friday on its “pivotal” 52-week randomised, double-blinded Phase III clinical trial of Lupuzor – its lead programme for the potential “breakthrough compound” for the life threatening autoimmune disease lupus. 

Asia report: Markets lower as tech stocks stumble

Most markets in Asia were lower on Friday, with tech shares in the region taking their cues from their Wall Street peers, as traders in most countries brushed off solid manufacturing data from China.